NCT07123493View on ClinicalTrials.gov

Engineered T-Cell Therapy for Patients With ALPP-Positive Advanced Solid Tumors

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2028

Conditions
Recurrent or Metastatic Solid Tumors With Positive ALPP
Interventions
BIOLOGICAL

Anti ALPP CAR-T cells treatment

Biological: anti ALPP CAR-T cells Treatment follows a lymphodepletion Drug: Fludarabine and Cyclophosphamide

Trial Locations (1)

102200

Beijing GoBroad Hospital, Beijing

All Listed Sponsors
lead

Haifeng Qin

OTHER